Table 2.
No. of events per patient with alogliptin or placebo during follow‐up of the EXAMINE trial
| Endpoints | Alogliptin, n = 2701 | Placebo, n = 2679 | Total, N = 5380 | P Value |
|---|---|---|---|---|
| No. of events per patient | ||||
| Mean ±SD | 1.6 ±1.1 (n = 545) | 1.6 ±1.2 (n = 555) | 1.6 ±1.2 (N = 1100) | 0.54 |
| Median (IQR) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | |
| Range (min, max) | 10.0 (1.0, 11.0) | 13.0 (1.0, 14.0) | 13.0 (1.0, 14.0) | |
| CV death | 112 (4.1) | 130 (4.9) | 242 (4.5) | 0.21 |
| Death | 153 (5.7) | 173 (6.5) | 326 (6.1) | 0.223 |
| No. of nonfatal events per patient | ||||
| Mean ± SD | 1.6 ± 1.1 (n = 462) | 1.7 ±1.3 (n = 449) | 1.7 ±1.2 (N = 911) | 0.91 |
| Median (IQR) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | |
| Range (min, max) | 10.0 (1.0, 11.0) | 13.0 (1.0, 14.0) | 13.0 (1.0, 14.0) |
Abbreviations: ACS, acute coronary syndrome; CV, cardiovascular; EXAMINE, Examination of Cardiovascular Outcomes With Alogliptin vs Standard of Care in patients with T2DM and ACS; IQR, interquartile range; max, maximum; min, minimum; SD, standard deviation; T2DM, type 2 diabetes mellitus.
Data are presented as n (%), mean ±SD, median (IQR), or range.